Conference Call and Webcast Today at 4:30 PM EDT SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-p ...

ALX Oncology Holdings Inc. (ALXO) has been on a downward spiral lately with significant selling pressure. After declining 30.8% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting w ...

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management will participate in the Jefferies Global Healthcare Conference. Details are as follows: Format: Fireside chat with analyst, Michael Yee and 1x1 Investor MeetingsDate: Wednesday, June 5, 2024 Time: 1:00 PM ET Location: New York, NY Webcast link: A ...

Group 1: Stock Performance and Price Targets - ALX Oncology Holdings Inc. (ALXO) closed at $15.61, with a 21.1% gain over the past four weeks, and a mean price target of $21.33 indicating a 36.6% upside potential [1] - The mean estimate includes six short-term price targets with a standard deviation of $4.59, suggesting variability in analyst estimates; the lowest estimate is $14 (10.3% decline), while the highest is $27 (73% increase) [1][4] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [4] Group 2: Analyst Sentiment and Earnings Estimates - Analysts show increasing optimism about ALXO's earnings prospects, with a strong agreement in revising EPS estimates higher, correlating with potential stock price increases [6] - Over the last 30 days, three estimates have been revised upward, leading to a 9.1% increase in the Zacks Consensus Estimate [6] - ALXO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential upside [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...

Exhibit 99.1 ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., May 9, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. "We entered the quarter with a great deal of momentum having achiev ...

ALX Oncology Holdings Inc. (ALXO) reported positive results from an ongoing phase I/II investigator-sponsored study of evorpacept, in combination with Roche’s (RHHBY) Rituxan (rituximab) and Bristol Myers’ (BMY) Revlimid (lenalidomide) (R2), to treat indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The early to mid-stage study is sponsored and conducted by MD Anderson Cancer Center, which is based in Texas.ALX Oncology announced that, per findings, patients receiving e ...

Core Insights - ALX Oncology reported promising clinical data from a Phase 1/2 trial of evorpacept combined with standard R2 treatment in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) [1][2][3] Group 1: Clinical Trial Results - The trial enrolled 20 patients, with 18 having indolent and 2 having aggressive R/R B-NHL, all of whom had prior rituximab treatment, and 72% had prior chemoimmunotherapy [2] - Evorpacept was administered at doses of 30 mg/kg every two weeks (n=3) or 60 mg/kg every four weeks (n=17), with no dose-limiting toxicities reported [2] - The combination therapy achieved a best overall response rate (ORR) of 94% and a complete response rate (CRR) of 83% in patients with indolent R/R B-NHL, significantly higher than the historical CRR benchmark of 34% for R2 alone [1][2] Group 2: Safety and Tolerability - The treatment was well tolerated, with common adverse events including fatigue, ALT increase, anemia, and AST increase, all primarily low grade [2] - No treatment-related deaths were reported during the study [2] Group 3: Future Directions - The ongoing Phase 2 portion of the trial will evaluate the evorpacept-R2 combination in previously untreated indolent B-NHL patients [4] - ALX Oncology aims to explore novel combinations with evorpacept to enhance anti-tumor activity through the innate immune response [3][6] Group 4: Company Overview - ALX Oncology is focused on developing therapies that block the CD47 immune checkpoint pathway, with evorpacept being a next-generation CD47 blocking therapeutic [6][7] - The company has dosed over 500 subjects with evorpacept, demonstrating promising activity and a favorable tolerability profile across various malignancies [6]

[ALX Oncology Q4 and Full Year 2023 Results & Corporate Update](index=1&type=section&id=ALX%20Oncology%20Reports%20Fourth%20Quarter%20and%20Full%20Year%202023%20Financial%20Results%20and%20Provides%20Corporate%20Update) ALX Oncology reports Q4 and full year 2023 financial results, corporate highlights, and clinical milestones for evorpacept [Corporate Highlights and Outlook](index=1&type=section&id=Corporate%20Highlights%20and%20Outlook) Significant 2023 growth driven by positive evorpacept trial results, capital raise, and upcoming clinical milestones - The CEO emphasized 2023 as a profound growth period, highlighted by positive randomized trial results for evorpacept in solid tumors, a first in the CD47 space[2](index=2&type=chunk) - The company plans to report multiple value-driving data points over the next 12-18 months from nine ongoing trials, aiming to expand evorpacept's application to **breast cancer**, **NHL**, **multiple myeloma**, and **urothelial cancers**[2](index=2&type=chunk) [Fourth Quarter 2023 Highlights](index=1&type=section&id=Fourth%20Quarter%202023%20Highlights) Q4 2023 highlights: leadership transition, positive ASPEN-06 interim data, and a successful **$63.2 million** public offering - Jason Lettmann was appointed CEO, with co-founder Jaume Pons transitioning to Chief Scientific Officer[3](index=3&type=chunk) ASPEN-06 Phase 2 Interim Results (Advanced Gastric/GEJ Cancer) | Metric | Evorpacept Combination Arm | Control Arm (TRP) | | :--- | :--- | :--- | | Confirmed Overall Response Rate (ORR) | 52% | 22% | | Median Duration of Response (mDOR) | Not Reached | 7.4 months | - The company executed an oversubscribed public offering, generating gross proceeds of approximately **$63.2 million**, extending the expected cash runway into early 2026[4](index=4&type=chunk)[5](index=5&type=chunk) [Anticipated 2024 Clinical Milestones](index=2&type=section&id=Anticipated%202024%20Clinical%20Milestones) ALX Oncology anticipates a catalyst-rich 2024 with multiple evorpacept data readouts and a planned Phase 3 trial in Gastric/GEJ Cancer - Key upcoming data presentations and results include: - **Non-Hodgkin Lymphoma:** Phase 1b data at AACR Annual Meeting (April 2024) - **Urothelial Carcinoma:** Phase 1b ASPEN-07 data (Q2 2024) - **Gastric/GEJ Cancer:** Top-line results from the full Phase 2 ASPEN-06 trial (June-July 2024) - **Breast Cancer:** Top-line results from the Phase 1b I-SPY TRIAL (Q4 2024) - **Head and Neck Cancer:** Top-line results from Phase 2 ASPEN-03 and ASPEN-04 trials (Q4 2024/Q1 2025)[6](index=6&type=chunk) - The company plans to initiate a Phase 3 registrational randomized clinical trial for evorpacept in Gastric/GEJ Cancer in Q4 2024[6](index=6&type=chunk) [2023 Full Year and Fourth Quarter Financial Results](index=2&type=section&id=2023%20Full%20Year%20and%20Fourth%20Quarter%20Financial%20Results) ALX Oncology concluded 2023 with **$218.1 million** in cash, a wider net loss due to increased R&D expenses, and a cash runway into early 2026 - As of December 31, 2023, the company held **$218.1 million** in cash, cash equivalents, and investments, with an additional **$40 million** available from a term loan, providing a cash runway into early 2026[7](index=7&type=chunk) Full Year Financial Comparison (2023 vs 2022, in millions) | Metric | FY 2023 ($M) | FY 2022 ($M) | | :--- | :--- | :--- | | R&D Expenses | $141.8 | $98.4 | | G&A Expenses | $28.5 | $29.0 | | GAAP Net Loss | ($160.8) | ($123.5) | | GAAP Net Loss per Share | ($3.74) | ($3.03) | Q4 Financial Comparison (2023 vs 2022, in millions) | Metric | Q4 2023 ($M) | Q4 2022 ($M) | | :--- | :--- | :--- | | R&D Expenses | $41.8 | $25.2 | | G&A Expenses | $6.2 | $7.0 | | GAAP Net Loss | ($45.5) | ($30.7) | | GAAP Net Loss per Share | ($0.93) | ($0.75) | [About ALX Oncology and Evorpacept](index=3&type=section&id=About%20ALX%20Oncology%20and%20Evorpacept) ALX Oncology develops evorpacept, a next-generation CD47 blocking therapeutic with an inactive Fc domain for improved safety and dual immune mechanism - The company's lead product, evorpacept, is a next-generation CD47 blocking therapeutic designed to bridge the innate and adaptive immune systems[12](index=12&type=chunk) - Evorpacept has been dosed in over **500 subjects** and has shown a favorable tolerability profile across various hematologic and solid malignancies[12](index=12&type=chunk) - Evorpacept is rationally engineered with an inactive Fc effector function, which provides a substantially improved safety profile over other anti-CD47 molecules, allowing for higher dosing with minimal overlapping toxicity[13](index=13&type=chunk) - The drug's dual mechanism of action involves: 1) enabling macrophage-mediated phagocytosis when combined with anti-cancer antibodies, and 2) enabling T-cell activation by dendritic cells when combined with PD-1/PD-L1 inhibitors[13](index=13&type=chunk)[14](index=14&type=chunk) [Financial Statements and Non-GAAP Reconciliation](index=5&type=section&id=Financial%20Statements%20and%20Non-GAAP%20Reconciliation) Consolidated financial statements detail operating expenses, net loss, and balance sheet, with a GAAP to non-GAAP net loss reconciliation for stock-based compensation Consolidated Statements of Operations (in thousands) | Line Item | Q4 2023 | Q4 2022 | FY 2023 | FY 2022 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $41,784 | $25,197 | $141,795 | $98,400 | | General and administrative | $6,239 | $7,022 | $28,483 | $29,036 | | **Total operating expenses** | **$48,023** | **$32,219** | **$170,278** | **$127,436** | | Loss from operations | ($48,023) | ($32,219) | ($170,278) | ($127,436) | | **Net loss** | **($45,472)** | **($30,709)** | **($160,805)** | **($123,482)** | | Net loss per share | ($0.93) | ($0.75) | ($3.74) | ($3.03) | Consolidated Balance Sheet Data (in thousands) | Line Item | Dec 31, 2023 | Dec 31, 2022 | | :--- | :--- | :--- | | Cash, cash equivalents and investments | $218,147 | $282,906 | | Total assets | $242,553 | $306,489 | | Total liabilities | $52,841 | $43,025 | | Total stockholders' equity | $189,712 | $263,464 | GAAP to Non-GAAP Net Loss Reconciliation (in thousands) | Line Item | Q4 2023 | Q4 2022 | FY 2023 | FY 2022 | | :--- | :--- | :--- | :--- | :--- | | GAAP net loss | ($45,472) | ($30,709) | ($160,805) | ($123,482) | | Stock-based compensation | $6,721 | $6,295 | $26,273 | $23,839 | | **Non-GAAP net loss** | **($38,687)** | **($24,370)** | **($134,282)** | **($99,599)** |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HOLDINGS INC. (Exact name of regis ...